19th Expert Committee: Applications for:

ADDITIONAL MEDICINES:

• Abacavir + lamivudine (Addition) -- Adults
• Abacavir + lamivudine (Addition) -- Children
• Artesunate + mefloquine (Addition) -- Adults and Children
• Atazanavir + ritonavir (Addition) -- Adults
• Azithromycin (Addition) -- Adults and Children
• Bedaquiline (Addition) -- Adults
• Bevacizumab (Addition) -- Adults
• Calcium (Addition) -- Adults
• Clozapine (Addition as complementary medicine) -- Adults
• Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults
• Fixed-dose combination for secondary prevention of cardiovascular disease (Addition) -- Adults
• Fomepizole (Addition) -- Adults and Children
• Human normal immunoglobulin (Additional dosage) -- Adults and Children
• Hydromorphone (Addition) -- Children
• Imatinib (Addition) -- Adults
• Imatinib (Addition) -- Adults and Children
• Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (Addition) -- Adults and Children
• Ketorolac (Addition) -- Adults
• Ketotifen (Addition) -- Adults and Children
• Lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults
• Latanoprost (Addition) -- Adults
• Montelukast (Addition) -- Children
• Naproxen (Addition) -- Adults
• Nifurtimox + eflornithine (Addition) -- Children
• Ofloxacin (Addition) -- Adults and Children
• Oxycodone (Addition) -- Children
• Pegylated interferon (Addition) -- Adults
• Risperidone (Addition) -- Adults
• Trastuzumab (Addition) -- Adults
• Whole blood and red blood cells (Addition) -- Adults and Children

ADDITIONAL FORMULATIONS:

• Abacavir (New formulation) -- Children
• Benznidazole (New formulation) -- Children
• Chlorhexidine (New formulation) -- Children
• Efavirenz (New formulation) -- Children
• Ferrous salt + folic acid (New formulation) -- Adults
• Lamivudine + nevirapine + zidovudine (New formulation) -- Children
• Lamivudine + stavudine (New formulation) -- Children
• Lamivudine + zidovudine (New formulation) -- Children
• Morphine (New formulation) -- Children
• Nevirapine (New formulation) -- Children

AGE RESTRICTION:

• Fluoxetine (Change to age restriction/Deletion from EMLc) -- Adults and Children

NEW INDICATION:

• Dexamethasone (New indication) -- Children
• Misoprostol (New indication) -- Adults
• Spironolactone (New indication) -- Adults

MOVE:

• Amphotericin (To be moved to core list) -- Adults and Children
• Flucytosine (To be moved to core list) -- Adults and Children
• Streptomycin (To be moved to complementary list) -- Children

NEW SECTION:

• Palliative care (New section) -- Children

POSSIBLE DELETION:

• Antiretrovirals (Formulations to be considered for possible deletion) -- Adults and Children
• Chlorpromazine and haloperidol (Deletion) -- Children only
• Dithranol (Deletion) -- Adults
• Fluoxetine (Change to age restriction/Deletion from EMLc) -- Adults and Children
• Misoprostol (Deletion) for PPH prevention -- Adults
• Oseltamivir (Deletion) -- Adults and Children

RE-INSTATEMENT:

• Colchicine (Re-instatement) -- Adults

REVIEW:

• Anaesthetics (Review) -- Children
• Antiarrhythmics (Review) -- Children
• Antiparkinsonism medicines (Review) -- Adults
• Antiulcer medicines (Review) -- Adults
• Benzoyl peroxide (Review) -- Adults and Children
• Coal tar (Review) -- Adults
• Colloids (Review) -- Children
• Ear, nose and throat (Review) -- Adults and Children
• Glibenclamide (Review) -- Adults
• Histamine-1 receptor antagonists (Review) -- Adults and Children
• Nifurtimox + eflornithine (Review) -- Adults and Children
• Oral hypoglycemics (Review) -- Adults
• Palliative care (Review) -- Adults
• Second-line antituberculosis medicines (Review) -- Children
• Statins (Review) -- Children